DNB Carnegie acted as joint bookrunner to Active Biotech in the fully guaranteed rights issue of approximately SEK 70 million.
Active Biotech is a Swedish biotech company focused on developing innovative immunomodulatory therapies for diseases with high unmet medical need in hematological malignancies (tasquinimod) and inflammatory eye diseases (laquinimod).